Business Insights, Aug 2010, Pages: 160
Driven by rising demand, patent expiries and pharmaceutical cost-containment policies, generic sales have risen consistently at rates in excess of the pharmaceutical industry average over the past
Datamonitor, March 2011, Pages: 81
to overcome these hurdles
- Provides an overview of various cost cutting strategies and how these are being implemented by Big Pharma
Highlights
- With the era of the traditional blockbuster growth model
Datamonitor, March 2010, Pages: 257
management strategies
8. Mergers and Acquisitions
M&A will remain a central strategy for Pharma
M&A deals to increase scale and cut costsM&A deals to target high growth therapeutic markets
M&A deals
GBI Research, Oct 2011, Pages: 92
because of the patent expiries of some of the major branded drugs as well as healthcare costcontainment measures. Generic sector APIs are expected to hold an increased share of the overall API
Datamonitor, Dec 2010, Pages: 267
.
Generics uptake is already high and the latest cost-containment measures including tendering contracts for generics have led to downward pricing spirals, negatively impacting the domestic generics industry
Decision Resources, Inc., Feb 2011, Pages: 28
Requirement for Value Dossiers
- New Price-Setting Procedures
- Changes to the Established Cost-ContainmentStrategy
- Industry Reactions to the Reforms
Italy
- Initiative to Promote More-Uniform Access
Datamonitor, July 2010, Pages: 195
generic usage, Italy employs a range of pricing and reimbursement tools to control costs. As a result, drug prices in Italy are among the lowest in Europe, a factor which is largely behind the country
Datamonitor, Aug 2010, Pages: 202
influencing the generic industry, 2010
Figure 35: Japan - growth of generics market, 2005-2010
Figure 36: Japan - brand sales at risk of generic erosion ($m), 2010-12
Figure 37: Japan - mean erosion
Datamonitor, July 2010, Pages: 111
: ongoing cost-containment measures
US
Current and future market assessment
The US antihormonals market will suffer the greatest impact of generic sales erosion
Opportunities and threats
Opportunity 1
GBI Research, Oct 2010, Pages: 114
“Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth”. The report provides a detailed insight into the global Active Pharmaceutical
Decision Resources, Inc., June 2010, Pages: 35
Health Care Act of 1992.
- Topics negotiated: Costcontainment, number of people insured, impact on federal deficit, anticipated savings, public plan, individual mandate, national insurance exchange
Datamonitor, July 2010, Pages: 114
Threat 3: in the long run, US health reform law will intensify cost-containment pressures
Japan
Current and future market assessment
The cytotoxics market in Japan will experience growth of nearly 2
Business Insights, May 2005, Pages: 131
Increased costcontainment
Opportunities in the pharmaceutical marketplace
Chapter 2 Failing short-term strategies
Summary
Introduction
Reliance on US revenues
Long-term sustainability
Increasing sales
Decision Resources, Inc., March 2009, Pages: 49
Elections
-Expanded Access
-CostContainment
-Cost-Effective, Quality Care
-Support for Innovation
-On the Economic Front: Quantifying the Impact of the Recession
-On the Approvals Front: Latisse Became
Decision Resources, Inc., Sep 2007, Pages: 37
: cost-containment measures by the Ministry of Health, Labor, and Welfare; Japan’s National Health Insurance system; biennial drug price revisions; increased emphasis on promoting generic drugs; the DPC
Taiyou Research, Nov 2011, Pages: 240
. The report contains an overall industry competitive profile, the market view of competition, the increasing role of multinationals in the industry along with an analysis of the major strategies of some major
